Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.39 |
| ▸ | PRKCA | P17252 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5197919 | 0.93 | KCNH2 (0.38) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL5199576 | 0.93 | KCNH2 (0.38) | KCNH2HRH3SCN9AL3MBTL1PTGER4 | |
| SCHEMBL5256740 | 0.92 | KCNH2 (0.36) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL5198317 | 0.91 | KCNH2 (0.42) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL5218711 | 0.91 | KCNH2 (0.40) | KCNH2HRH3PRKCAMMP12DHODH | |
| SCHEMBL5220941 | 0.90 | KCNH2 (0.37) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL5218899 | 0.90 | KCNH2 (0.39) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL5223263 | 0.90 | KCNH2 (0.36) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL27711026 | 0.90 | HRH3 (0.46) | KCNH2HRH3PRKCAMMP12SCN9A | |
| SCHEMBL5196593 | 0.90 | KCNH2 (0.37) | KCNH2HRH3PRKCAMMP12SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| CN-101103026-A | Bicyclic heteroaryl derivatives for treating viruses | GENELABS INC (US) | 2008-01-09 | — | — | CN | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | KCNH2 3202/4885HRH3 3113/4885PRKCA 4500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.